{"DataElement":{"publicId":"3005481","version":"1","preferredName":"Current Chronic Graft Versus Host Disease Immunosuppressive Therapy Intensity Category","preferredDefinition":"Categorization to capture the intensity of current immunosuppression therapy given for the treatment of chronic Graft versus Host Disease (GVHD).","longName":"CGVHD_IMM_INT_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3005474","version":"1","preferredName":"Current Chronic Graft Versus Host Disease Immunosuppressive Therapy Intensity","preferredDefinition":"Occurring in or belonging to the present time._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation._Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs._The degree or magnitude of strength, energy, or feeling.","longName":"CGVHD_IMM_TX_INT","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3005472","version":"1","preferredName":"Current Chronic Graft Versus Host Disease Immunosuppressive Therapy","preferredDefinition":"Occurring in or belonging to the present time.:A syndrome of immologically mediated tissue damage occurring following allogeneic transplant and may affect multiple organs with manifestations similar to autoimmune diseases.  Onset is usually within three years of transplantation or immunologic manipulation.:deliberate suppression of immune system function for experimental or therapeutic purposes.","longName":"C25471:C4981:C15261","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-45DE-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2632640","version":"1","preferredName":"Intensity","preferredDefinition":"The degree or magnitude of strength, energy, or feeling.","longName":"C25539","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F05E5B0-7C74-2F6C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-26","endDate":null,"createdBy":"UMLLOADER_BIOCONDUCTER","dateCreated":"2007-04-26","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-45EC-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3005476","version":"1","preferredName":"Immunosuppressive Therapy Intensity Category","preferredDefinition":"Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs._The degree or magnitude of strength, energy, or feeling._Category; used informally to mean a class of things.","longName":"IMM_TX_INT_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"High","valueDescription":"High (2 or more agents/modalities +/- prednisone >= 0.5 mg/kg/day)","ValueMeaning":{"publicId":"3005477","version":"1","preferredName":"High (2 or more agents/modalities +/- prednisone >= 0.5 mg/kg/day)","longName":"3005477","preferredDefinition":"High (2 or more agents/modalities +/- prednisone >= 0.5 mg/kg/day)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-4625-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EAFA041-463E-70AD-E040-BB89AD436D7B","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","deletedIndicator":"No"},{"value":"Moderate","valueDescription":"Moderate (prednisone  >= 0.5 mg/kg/day and/or any single agent/modality)","ValueMeaning":{"publicId":"3005478","version":"1","preferredName":"Moderate (prednisone  >= 0.5 mg/kg/day and/or any single agent/modality)","longName":"3005478","preferredDefinition":"Moderate (prednisone  >= 0.5 mg/kg/day and/or any single agent/modality)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-4648-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EAFA041-4661-70AD-E040-BB89AD436D7B","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","deletedIndicator":"No"},{"value":"Mild","valueDescription":"Mild (single agent prednisone <0.5 mg/kg/day)","ValueMeaning":{"publicId":"3005479","version":"1","preferredName":"Mild (single agent prednisone <0.5 mg/kg/day)","longName":"3005479","preferredDefinition":"Mild (single agent prednisone <0.5 mg/kg/day)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-466B-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EAFA041-4684-70AD-E040-BB89AD436D7B","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EAFA041-468E-70AD-E040-BB89AD436D7B","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3005475","version":"1","preferredName":"Immunosuppressive Therapy Intensity Category","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.:The degree or magnitude of strength, energy, or feeling.:Category; used informally to mean a class of things.","longName":"C15261:C25539:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intensity","conceptCode":"C25539","definition":"The degree or magnitude of strength, energy, or feeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-4601-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-4612-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"ONEDATA","dateModified":"2010-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Intensity of immunosuppression","type":"Preferred Question Text","description":"Intensity of immunosuppression","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EAFA041-4698-70AD-E040-BB89AD436D7B","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-03","modifiedBy":"REEVESD","dateModified":"2011-02-08","changeDescription":"Curated to support CCR Transplantation trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}